艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎的临床疗效及对患者骨代谢的影响

Clinical Efficacy of Iguratimod Combined with Methotrexate in the Treatment of Rheumatoid Arthritis and the Influence on Patients'Bone Metabolism

目的 探讨艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎(RA)的临床效果及对患者骨代谢的影响。方法 将我院收治的86例RA患者随机分为两组各43例。对照组采用甲氨蝶呤治疗,观察组采用艾拉莫德联合甲氨蝶呤治疗。比较两组的临床疗效、骨代谢指标(β-CTX、 TPINP、 N-MID)及不良反应发生情况。结果 观察组治疗总有效率为95.35%,明显高于对照组的81.40%(P<0.05)。治疗后,两组的β-CTX水平降低, TPINP、 N-MID水平升高(P<0.05);观察组的β-CTX水平明显低于对照组, TPINP、 N-MID水平高于对照组(P<0.05)。两组的不良反应发生率(9.30%vs. 6.98%)比较差异无统计学意义(P>0.05)。结论 艾拉莫德联合甲氨蝶呤治疗RA效果显著,可有效改善患者的骨代谢,且安全性较高。

Objective To analyze the clinical efficacy of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis(RA)and the incluence on patients'bone metabolism.Methods 86 RA patients admitted to our hospital were randomly divided into two groups,with 43 cases in each group.The control group was treated with methotrexate,and the observation group was treated with iguratimod combined with methotrexate.The clinical efficacy,bone metabolism indicators(β-CTX,TPINP,N-MID)and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.35%,significantly higher than 81.40%in the control group(P<0.05).After treatment,theβ-CTX levels of the two groups decreased,while the TPINP and N-MID levels increased(P<0.05);Theβ-CTX level of the observation group was lower than that of the control group,and the TPINP and N-MID levels were higher than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions(9.30%vs.6.98%)between the two groups(P>0.05).Conclusions Iguratimod combined with methotrexate has significant effect in the treatment of RA,which can effectively improve the bone metabolism of patients,with higher safety.